<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="data-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">WT6XKNXq89yGkHpzVxfzvcr</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2026000701803</article-id>
      <article-id pub-id-type="other">01803</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20260066</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Cient&#237;fica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Quiloperic&#225;rdio Prim&#225;rio Idiop&#225;tico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0001-9656-8703</contrib-id>
          <name>
            <surname>Ruffo</surname>
            <given-names>Camila Helena</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8060-221X</contrib-id>
          <name>
            <surname>Rosa</surname>
            <given-names>Alfredo Aur&#233;lio Marinho</given-names>
            <suffix>Filho</suffix>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0003-4633-8429</contrib-id>
          <name>
            <surname>Favaro</surname>
            <given-names>Guilherme Lima</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3842-8355</contrib-id>
          <name>
            <surname>Hirose</surname>
            <given-names>Juliana Sayuri Maia</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0000-5307-890X</contrib-id>
          <name>
            <surname>Lewinter</surname>
            <given-names>Raissa Matias</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0009-0856-4357</contrib-id>
          <name>
            <surname>Melillo</surname>
            <given-names>Natan</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0003-4756-7258</contrib-id>
          <name>
            <surname>Silva</surname>
            <given-names>Leonardo Izzo</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0002-7010-6305</contrib-id>
          <name>
            <surname>Anbar</surname>
            <given-names>Ramez</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coelho</surname>
            <given-names>Murilo Martins</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1010-2428</contrib-id>
          <name>
            <surname>Generoso</surname>
            <given-names>Giuliano</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados;</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Hospital S&#237;rio - Liban&#234;s</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital S&#237;rio - Liban&#234;s, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"><label>Correspond&#234;ncia:</label> Camila Helena Ruffo Hospital S&#237;rio - Liban&#234;s - Rua Prof. Daher Cutait, 69. CEP 01308-060, S&#227;o Paulo, SP &#8211; Brasil E-mail: <email>camilahruffo@gmail.com</email> </corresp>
        <fn fn-type="coi-statement">
          <label>Potencial Conflito de Interesse:</label>
          <p> Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
        <fn fn-type="edited-by">
          <label>Editor respons&#225;vel pela revis&#227;o:</label>
          <p> Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>18</day>
        <month>09</month>
        <year>2026</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2026</year>
      </pub-date>
      <volume>123</volume>
      <issue>7</issue>
      <elocation-id>e20260062</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>01</month>
          <year>2026</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>05</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>06</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="pt">
          <license-p>Este &#233; um artigo de acesso aberto distribu&#237;do sob os termos da licen&#231;a de atribui&#231;&#227;o pelo Creative Commons</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>Peric&#225;rdio</kwd>
        <kwd>Derrame Peric&#225;rdico</kwd>
        <kwd>Diagn&#243;stico por Imagem</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement><bold>Fontes de Financiamento:</bold> O presente estudo n&#227;o teve fontes de financiamento externas.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="12"/>
        <table-count count="4"/>
        <equation-count count="0"/>
        <ref-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>O quiloperic&#225;rdio &#233; uma entidade rara, definida pelo ac&#250;mulo de quilo no espa&#231;o peric&#225;rdico caracterizando-se por elevada concentra&#231;&#227;o de triglicer&#237;deos e predom&#237;nio linfocit&#225;rio. A primeira descri&#231;&#227;o foi em 1954 e desde ent&#227;o essa condi&#231;&#227;o permanece pouco frequente, com a maior parte das evid&#234;ncias provenientes de relatos de caso e pequenas s&#233;ries, o que dificulta o reconhecimento precoce e a padroniza&#231;&#227;o do manejo.</p>
      <p>As principais causas incluem linfangiectasia cong&#234;nita, les&#227;o iatrog&#234;nica ap&#243;s cirurgia card&#237;aca ou tor&#225;cica, neoplasias, traumas, infec&#231;&#227;o, radia&#231;&#227;o, hipertens&#227;o pulmonar, trombose de veia subcl&#225;via e causas prim&#225;rias ou idiop&#225;ticas. O quiloperic&#225;rdio prim&#225;rio, tem incid&#234;ncia vari&#225;vel na literatura e constitui diagn&#243;stico de exclus&#227;o.</p>
      <p>Relatamos um caso de quiloperic&#225;rdio prim&#225;rio em paciente jovem, enfatizando os desafios diagn&#243;sticos e terap&#234;uticos dessa condi&#231;&#227;o rara.</p>
    </sec>
    <sec>
      <title>Descri&#231;&#227;o</title>
      <p>Paciente do sexo feminino, 31 anos, previamente h&#237;gida, natural e procedente de S&#227;o Paulo (SP), procurou atendimento m&#233;dico, em contexto ambulatorial, com queixa de cansa&#231;o progressivo, fadiga e intoler&#226;ncia ao esfor&#231;o, iniciado h&#225; 5 meses. Relatava dispneia aos esfor&#231;os m&#237;nimos, associada a tontura, sensa&#231;&#227;o de desequil&#237;brio e sudorese diurna, com piora gradual ao longo dos meses. Negava dor tor&#225;cica, febre, tosse, emagrecimento, sintomas infecciosos ou hist&#243;ria de trauma tor&#225;cico ou cirurgias pr&#233;vias. De antecedentes pessoais, apresentava bronquite e estava em investiga&#231;&#227;o de amenorreia prim&#225;ria, com suspeita de s&#237;ndrome de Mayer&#8211;Rokitansky&#8211;K&#252;ster&#8211;Hauser. Negava tabagismo, etilismo ou uso de drogas il&#237;citas.</p>
      <p>No exame f&#237;sico inicial paciente mostrava-se em bom estado geral, com PA:129x67 mmHg, FC:65 bpm, FR:16 mrpm, satura&#231;&#227;o de oxig&#234;nio 97% em ar ambiente, afebril, sem sinais de congest&#227;o sist&#234;mica, com exame cardiovascular e respirat&#243;rio sem altera&#231;&#245;es significativas.</p>
      <p>A investiga&#231;&#227;o inicial incluiu eletrocardiograma, exames laboratoriais, sem achados espec&#237;ficos, e uma radiografia de t&#243;rax (<xref ref-type="fig" rid="f01">Figura 1</xref>) com evidente aumento da silhueta card&#237;aca. A partir desse achado, foi solicitado ecocardiograma transtor&#225;cico, que evidenciou derrame peric&#225;rdico de moderado volume, sem sinais de tamponamento card&#237;aco.</p>
      <p>
        <fig id="f01">
          <label>Figura 1</label>
          <caption>
            <title>&#8211; RX de t&#243;rax: aumento da silhueta card&#237;aca.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf01.tif"/></fig>
      </p>
      <p>Optado assim por interna&#231;&#227;o hospitalar para investiga&#231;&#227;o de etiologia do derrame peric&#225;rdico com exames laboratoriais como provas reumatol&#243;gicas, infecciosas, metab&#243;licas e exames de imagem complementar.</p>
      <p>A an&#225;lise complementar mostrou hemograma, eletr&#243;litos, parcial de urina, fun&#231;&#227;o renal, hep&#225;tica e tireoidiana normais, al&#233;m de marcadores inflamat&#243;rios discretamente alterados: PCR:1,02 mg/dL(VR&lt;0,5mg/dL) e VHS:41 mm (VR:2-20mm). A avalia&#231;&#227;o reumatol&#243;gica demonstrou altera&#231;&#245;es inespec&#237;ficas e discretas, as quais, n&#227;o determinam diagn&#243;stico reumatol&#243;gico (<xref ref-type="table" rid="t1">Tabela 1</xref>).</p>
      <p>
        <table-wrap id="t1">
          <label>Tabela 1</label>
          <caption>
            <title>&#8211; Resultados dos exames de investiga&#231;&#227;o reumatol&#243;gica</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Exames</th>
                <th>Resultados</th>
                <th>Valor de refer&#234;ncia</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>FAN</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>FR</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>C3</td>
                <td align="center">145mg/dL</td>
                <td align="center">81-157mg/dL</td>
              </tr>
              <tr>
                <td>C4</td>
                <td align="center">46mg/dL</td>
                <td align="center">13-39mg/dL</td>
              </tr>
              <tr>
                <td>ASLO</td>
                <td align="center">592UI/mL</td>
                <td align="center">&lt;200UI/mL</td>
              </tr>
              <tr>
                <td>Anticoagulante l&#250;pico</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-DsDNA</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-Jo 1</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-SCL 70</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-SSBLA</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-SSBRo</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-Sm</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anti-RNP</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Anticardiolipina</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Alfa-1 glicoprote&#237;na &#225;cida</td>
                <td align="center">73mg/dL</td>
                <td align="center">50-120mg/dL</td>
              </tr>
              <tr>
                <td>ANCA</td>
                <td align="center">negativo</td>
                <td align="center">negativo</td>
              </tr>
              <tr>
                <td>Creatinina urin&#225;ria</td>
                <td align="center">20mg/kg/dia</td>
                <td align="center">11-20mg/kg/dia</td>
              </tr>
              <tr>
                <td>Eletroforese de prote&#237;na</td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td>Albumina</td>
                <td align="center">53%</td>
                <td align="center">55-66%</td>
              </tr>
              <tr>
                <td>Beta-globulina</td>
                <td align="center">6,5%</td>
                <td align="center">3,2-6,5%</td>
              </tr>
              <tr>
                <td>Gama-globulina</td>
                <td align="center">21%</td>
                <td align="center">11-18%</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1">
              <p>FAN: fator antin&#250;cleo; FR: fator reumatoide; C3: complemento C3, C4: complemento C4; ASLO: antiestreptolisina O; Anti-DSDNA: anticorpo anti DNA nativo; Anti-Jo1: anticorpo anti- Jo1; Anti-SCL70: anticorpo anti-SCL70; Anti-SSBLA: anticorpo anti SSBLA: Anti-SSARo: anticorpo anti SSARo; Anti-SM: anticorpo anti SM; Anti-RNP: anticorpo anti RNP; ANCA: anticorpos anti- citoplasma de neutr&#243;filos.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Para melhor defini&#231;&#227;o anat&#244;mica, foi submetida a resson&#226;ncia magn&#233;tica card&#237;aca que demonstrou fun&#231;&#227;o sist&#243;lica biventricular preservada, aus&#234;ncia de fibrose mioc&#225;rdica e presen&#231;a do derrame peric&#225;rdico sem outras altera&#231;&#245;es (<xref ref-type="fig" rid="f02">Figura 2</xref>).</p>
      <p>
        <fig id="f02">
          <label>Figura 2</label>
          <caption>
            <title>&#8211; Resson&#226;ncia Magn&#233;tica Card&#237;aca demonstrando peric&#225;rdio com discreto espessamento e derrame discreto a moderado.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf02.tif"/></fig>
      </p>
      <p>Ao final da investiga&#231;&#227;o, a paciente recebeu alta com tratamento emp&#237;rico para poss&#237;vel pericardite viral com colchicina 0,5mg 2x ao dia e ibuprofeno 400mg 2x ao dia, com melhora parcial dos sintomas ap&#243;s 4 semanas.</p>
      <p>Realizado novo ecocardiograma transtor&#225;cico de controle ap&#243;s 4 semanas e identificado aumento do derrame peric&#225;rdico (25mm), aumento da ecogenicidade e <italic>swing heart</italic>. (<xref ref-type="fig" rid="f03">Figura 3</xref>). A partir desse achado, foi encaminhada &#224; sala de emerg&#234;ncia em bom estado geral, assintom&#225;tica, com PA:111x59 mmHg, FC:58 bpm, FR:13 mrpm e satura&#231;&#227;o de oxig&#234;nio 97% em ar ambiente, exame f&#237;sico normal e sem sinais cl&#237;nicos de tamponamento card&#237;aco. O eletrocardiograma com &#250;nico achado de supradesnivelamento do segmento ST, discreto e difuso, do tipo repolariza&#231;&#227;o precoce - achado comum em jovens, inespec&#237;fico e que se manteve ao longo da interna&#231;&#227;o (<xref ref-type="fig" rid="f04">Figura 4</xref>).</p>
      <p>
        <fig id="f03">
          <label>Figura 3</label>
          <caption>
            <title>&#8211; Ecocardiograma transtor&#225;cico. 1- janela longitudinal eixo longo. 2- janela longitudinal eixo curto. 3- janela apical 4 c&#226;maras. 4- janela subxifoide demonstrando restri&#231;&#227;o do enchimento do ventr&#237;culo direito. Setas: derrame peric&#225;rdico.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf03.tif"/></fig>
      </p>
      <p>
        <fig id="f04">
          <label>Figura 4</label>
          <caption>
            <title>&#8211; Ritmo sinusal, eixo preservado, discreto supra de ST difuso e sem sinais sugestivos de tamponamento card&#237;aco.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf04.tif"/></fig>
      </p>
      <p>Optado, portanto, pela realiza&#231;&#227;o de drenagem peric&#225;rdica de urg&#234;ncia com aux&#237;lio de v&#237;deotoracoscopia, com sa&#237;da de 400 mL de l&#237;quido amarelado, espesso e aspecto quiloso e visualizado peric&#225;rdio espessado e com aspecto fibrinoso. (<xref ref-type="fig" rid="f05">Figura 5</xref>) A an&#225;lise do l&#237;quido peric&#225;rdico revelou triglicer&#237;deos de 984 mg/dl, colesterol total de 83 mg/dl, rela&#231;&#227;o colesterol/triglicer&#237;deos de 0,08 e predom&#237;nio linfocit&#225;rio (89%), confirmando o diagn&#243;stico de quiloperic&#225;rdio. Perfil lip&#237;dico da paciente demonstrou CT:174 mg/Ll, TG:35 mg/dL, LDL-c:116 mg/dL e HDL-c:47 mg/dL. Demais an&#225;lise do l&#237;quido peric&#225;rdio com pH:7,4, prote&#237;na:4,4 g/L, LDH:153 mg/dL, albumina: 2,9 g/L, amilase:93 mg/dL, glicose:90 mg/dL, pesquisa para tuberculose (ADA, BAAR e TR-TB) negativas, PCR-CMV, micol&#243;gico direto, citologia onc&#243;tica e culturas todos negativos. A bi&#243;psia peric&#225;rdica demonstrou pericardite fibrinosa cr&#244;nica em organiza&#231;&#227;o.</p>
      <p>
        <fig id="f05">
          <label>Figura 5</label>
          <caption>
            <title>&#8211; Aspecto macrosc&#243;pico do l&#237;quido peric&#225;rdico.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf05.tif"/></fig>
      </p>
      <p>Ap&#243;s o estabelecimento do diagn&#243;stico de quiloperic&#225;rdio, a investiga&#231;&#227;o etiol&#243;gica incluiu tomografia computadorizada de t&#243;rax, sem altera&#231;&#245;es ou presen&#231;a de massas, e linfocintilografia (<xref ref-type="fig" rid="f06">Figura 6</xref>) &#8211; que demonstrou d&#233;ficit de drenagem linf&#225;tica funcional difuso, sem sinais de refluxo d&#233;rmico (sinal de linfedema), obstru&#231;&#227;o ou dilata&#231;&#227;o dos vasos linf&#225;ticos, drenagem an&#244;mala ou aumento de capta&#231;&#227;o em regi&#245;es linfonodais.</p>
      <p>
        <fig id="f06">
          <label>Figura 6</label>
          <caption>
            <title>&#8211; Linfocintilografia &#233; realizado com a inje&#231;&#227;o de radiof&#225;rmaco de forma subcut&#226;nea entre os dedos das m&#227;os e dos p&#233;s, sendo captado pelo sistema linf&#225;tico e transportado ao longo dos vasos linf&#225;ticos; utilizado para avalia&#231;&#227;o de fluxo linf&#225;tico, integridades dos vasos, linfonodos e refluxo d&#233;rmico (presente em casos de linfedema). A paciente em quest&#227;o apresentou achados de d&#233;ficit funcional da drenagem linf&#225;tica de forma difusa. Sem evid&#234;ncias de obstru&#231;&#245;es, malforma&#231;&#245;es cong&#234;nitas ou f&#237;stulas do ducto linf&#225;tico.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf06.tif"/></fig>
      </p>
      <p>Exclu&#237;das causas secund&#225;rias, a paciente recebeu tratamento para quiloperic&#225;rdio prim&#225;rio com dieta hipogordurosa e hiperproteica, associada &#224; manuten&#231;&#227;o da drenagem peric&#225;rdica.</p>
      <p>No p&#243;s- operat&#243;rio, a PA oscilou entre 100-138x59-85 mmhg, a FC entre 51-95 bpm e a FR entre13-20 mrpm. Em avalia&#231;&#227;o di&#225;ria, houve redu&#231;&#227;o progressiva do d&#233;bito do l&#237;quido peric&#225;rdico e queda sustentada dos n&#237;veis de triglicer&#237;deos, sendo optado pela retirada do dreno ap&#243;s 10 dias do procedimento. O ecocardiograma transtor&#225;cico de controle n&#227;o observou sinais de derrame peric&#225;rdico e paciente recebeu alta com 11 dias de interna&#231;&#227;o hospitalar (<xref ref-type="table" rid="t2">Tabela 2</xref>).</p>
      <p>
        <table-wrap id="t2">
          <label>Tabela 2</label>
          <caption>
            <title>&#8211; Temporalidade dos eventos do caso</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Evento</th>
                <th>Tempo / Refer&#234;ncia</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>In&#237;cio dos sintomas</td>
                <td align="center">5 meses antes da 1&#186; consulta</td>
              </tr>
              <tr>
                <td>1&#186; consulta ambulatorial</td>
                <td align="center">Dia 0 (refer&#234;ncia)</td>
              </tr>
              <tr>
                <td>ECG, RX de t&#243;rax, exames laboratoriais iniciais</td>
                <td align="center">Dia 2</td>
              </tr>
              <tr>
                <td>Ecocardiograma transtor&#225;cico &#8211; derrame peric&#225;rdico moderado sem tamponamento</td>
                <td align="center">Dia 7</td>
              </tr>
              <tr>
                <td>Interna&#231;&#227;o hospitalar para investiga&#231;&#227;o etiol&#243;gica</td>
                <td align="center">Dia 13</td>
              </tr>
              <tr>
                <td>Exames laboratoriais ampliados (reumatol&#243;gicos, infecciosos, metab&#243;licos)</td>
                <td align="center">Durante 1&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>Resson&#226;ncia magn&#233;tica card&#237;aca &#8211; fun&#231;&#227;o preservada, derrame peric&#225;rdico sem outras altera&#231;&#245;es</td>
                <td align="center">Durante 1&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>Alta hospitalar com tratamento emp&#237;rico (colchicina+ ibuprofeno)</td>
                <td align="center">Dia 7 da 1&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>Retorno ambulatorial com ecocardiograma de controle &#8211; por&#225; do derrame (25mm), swing heart</td>
                <td align="center">Semana 4 ap&#243;s alta</td>
              </tr>
              <tr>
                <td>Encaminhamento &#225; emerg&#234;ncia</td>
                <td align="center">Semana 4</td>
              </tr>
              <tr>
                <td>Drenagem peric&#225;rdica por videotoracoscopia &#8211; sa&#237;da de 400 mL de l&#237;quido quiloso</td>
                <td align="center">Dia 1 da 2&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>An&#225;lise do l&#237;quido peric&#225;rdico &#8211; diagn&#243;stico confirmado de quiloperic&#225;rdio</td>
                <td align="center">Dia 2 da 2&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>TC de t&#243;rax e linfocintilografia &#8211; investiga&#231;&#227;o etiol&#243;gica complementar</td>
                <td align="center">Dia 3 da 2&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>Retirada do dreno peric&#225;rdico</td>
                <td align="center">Dia 10 do p&#243;s operat&#243;rio</td>
              </tr>
              <tr>
                <td>Ecocardiograma de controle &#8211; sem derrame</td>
                <td align="center">Dia 11 do p&#243;s operat&#243;rio</td>
              </tr>
              <tr>
                <td>Alta hospitalar</td>
                <td align="center">Dia 11 da 2&#170; interna&#231;&#227;o</td>
              </tr>
              <tr>
                <td>Seguimento ambulatorial</td>
                <td align="center">Ap&#243;s a alta, sem recorr&#234;ncia</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2">
              <p>ECG: eletrocardiograma; RX: raio x; TC: tomografia computadorizada.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Atualmente, a paciente segue em acompanhamento ambulatorial, assintom&#225;tica e com evolu&#231;&#227;o favor&#225;vel e ecocardiogramas de controle ap&#243;s 3 e 6 meses e 1 ano sem novo epis&#243;dio de derrame peric&#225;rdico.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>O quiloperic&#225;rdio &#233; uma condi&#231;&#227;o rara caracterizada pelo ac&#250;mulo de l&#237;quido linf&#225;tico rico em triglicer&#237;deos (quilo) no espa&#231;o peric&#225;rdico. Desde o primeiro relato de Groves<sup><xref ref-type="bibr" rid="B1">1</xref></sup> em 1954, esse acometimento permanece pouco frequente, sendo a maior parte do conhecimento derivada de relatos de casos e pequenas s&#233;ries, o que contribui para limita&#231;&#245;es na padroniza&#231;&#227;o diagn&#243;stica e terap&#234;utica. Uma metan&#225;lise realizada pela Mayo Clinic encontrou apenas 33 casos em uma d&#233;cada de estudo, entre o per&#237;odo de 1996 a 2006.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>A drenagem linf&#225;tica do peric&#225;rdio &#233; majoritariamente direcionada aos linfonodos mediastinais e peritraqueobr&#244;nquicos (75%) ou ascendendo &#224;s veias braquicef&#225;licas (25%). N&#227;o h&#225; relato de vasos linf&#225;ticos que entrem diretamente no espa&#231;o peric&#225;rdio e que possam causar ac&#250;mulo de quilo na cavidade, todos permanecem no lado pleural do peric&#225;rdio fibroso. No entanto o mecanismo fisiopatol&#243;gico mais prov&#225;vel para a presen&#231;a de quilo no espa&#231;o peric&#225;rdio seria decorrente do refluxo dos vasos linf&#225;ticos mediastinais e traqueobr&#244;nquicos.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>O quadro cl&#237;nico &#233; vari&#225;vel e inespec&#237;fico. A maioria dos pacientes permanecem assintom&#225;ticos, enquanto outros apresentam dispneia progressiva, fadiga, intoler&#226;ncia ao esfor&#231;o e, em casos graves, tamponamento card&#237;aco.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> De acordo com metan&#225;lises recentes aproximadamente 74% dos pacientes apresentavam sintomas no momento do diagn&#243;stico, sendo a dispneia o mais comum e 38% com tamponamento card&#237;aco,<sup><xref ref-type="bibr" rid="B5">5</xref></sup> com um intervalo entre o in&#237;cio dos sintomas at&#233; o diagn&#243;stico de cerca de 13 anos.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> O curso cl&#237;nico insidioso observado no presente caso est&#225; de acordo com esse padr&#227;o descrito na literatura.</p>
      <p>A epidemiologia &#233; incerta, com estudos mais atuais sugerindo at&#233; 60% dos casos s&#227;o idiop&#225;ticos prim&#225;rios, acometendo predominantemente adultos jovens, sem clara predomin&#226;ncia entre os sexos.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> As causas secund&#225;rias incluem cirurgia card&#237;aca ou tor&#225;cica, trauma, neoplasias linf&#225;ticas ou outras neoplasias mediastinais (linfangioma mediastinal, disgerminoma mediastinal, carcinoma de c&#233;lulas em anel de sinete), s&#237;ndrome de Gorham, radioterapia, infec&#231;&#245;es, tuberculose, hipertens&#227;o pulmonar, trombose venosa e linfangiectasia mediastinal.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup> Na aus&#234;ncia desses fatores, como no caso apresentado, o diagn&#243;stico de quiloperic&#225;rdio prim&#225;rio deve ser considerado como de exclus&#227;o. Acredita-se que o ac&#250;mulo de l&#237;quido linf&#225;tico ocorra por comunica&#231;&#245;es anormais do ducto tor&#225;cico com os vasos linf&#225;ticos peric&#225;rdicos ou pela eleva&#231;&#227;o da press&#227;o no ducto tor&#225;cico, como o que ocorre na linfangiectasia.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>A investiga&#231;&#227;o etiol&#243;gica deve ser sistem&#225;tica, especialmente nos casos sem causa aparente. As diretrizes da Sociedade Europeia de Cardiologia (ESC) recomendam investiga&#231;&#227;o etiol&#243;gica dirigida em derrames peric&#225;rdicos volumosos, recorrentes ou de etiologia indeterminada.<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
      <p>O diagn&#243;stico definitivo baseia-se na an&#225;lise do l&#237;quido peric&#225;rdico. N&#237;veis de triglicer&#237;deos superiores a 500 mg/dl, rela&#231;&#227;o colesterol/triglicer&#237;deos inferior a 1, predom&#237;nio linfocit&#225;rio e aspecto macrosc&#243;pico leitoso ou amarelado s&#227;o crit&#233;rios amplamente aceitos para confirma&#231;&#227;o diagn&#243;stica.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Culturas geralmente s&#227;o negativas, uma vez que o quilo possui propriedades bacteriost&#225;ticas.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> No nosso caso, os achados laboratoriais do l&#237;quido peric&#225;rdico foram compat&#237;veis com a literatura, permitindo confirma&#231;&#227;o do diagn&#243;stico.</p>
      <p>Devido a alta incid&#234;ncia de tuberculose em nosso pa&#237;s, foram realizadas an&#225;lises espec&#237;ficas e comparadas com achados da literatura. Derrame peric&#225;rdico por tuberculose geralmente apresenta-se como de aspecto hemorr&#225;gico, exsudativo, com alto teor de prote&#237;na, leuc&#243;citos com predom&#237;nio de linf&#243;citos e mon&#243;citos.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Nossos achados v&#227;o de encontro com a possibilidade de tuberculose, al&#233;m dos resultados negativos para ADA, BAAR, TR-TB, cultura e an&#225;lise histol&#243;gica.</p>
      <p>O ecocardiograma transtor&#225;cico &#233; o exame inicial de escolha para avalia&#231;&#227;o do derrame peric&#225;rdico e repercuss&#227;o hemodin&#226;mica. Demais m&#233;todos de imagem complementares, como tomografia computadorizada e resson&#226;ncia magn&#233;tica card&#237;aca, s&#227;o &#250;teis para exclus&#227;o de neoplasias e outras causas secund&#225;rias.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup> Outras formas de se avaliar a drenagem linf&#225;tica &#233; atrav&#233;s da ingesta de corante Sudan III ou esp&#233;cie de triglicer&#237;deos marcado com iodo radioativo.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> A linfocintilografia e a linfangiografia auxiliam na identifica&#231;&#227;o de altera&#231;&#245;es do ducto tor&#225;cico ou comunica&#231;&#245;es linf&#225;ticas an&#244;malas, sendo particularmente indicadas em casos recorrentes ou refrat&#225;rios.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
      <p>No presente relato a paciente apresenta d&#233;ficit de drenagem linf&#225;tica funcional, n&#227;o demonstrando obstru&#231;&#245;es, comunica&#231;&#245;es an&#244;malas ou refluxo d&#233;rmico. Esse achado foi interpretado como constitucional da paciente, visto que durante toda a interna&#231;&#227;o n&#227;o apresentou edema ou sinais de reten&#231;&#227;o h&#237;drica.</p>
      <p>O manejo terap&#234;utico permanece desafiador devido &#224; escassez de dados robustos. Estrat&#233;gias conservadoras incluem drenagem peric&#225;rdica associada a dieta hipogordurosa, preferencialmente com triglicer&#237;deos de cadeia m&#233;dia, suporte nutricional e, em casos selecionados, uso de octreot&#237;deo.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup>Apesar disso, aproximadamente um ter&#231;o dos pacientes evolui com falha do tratamento cl&#237;nico, necessitando de interven&#231;&#227;o cir&#250;rgica, como ligadura do ducto tor&#225;cico e cria&#231;&#227;o de janela peric&#225;rdica.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> No caso apresentado, o tratamento com drenagem peric&#225;rdica associada a dieta hipogordurosa foi eficaz, com resolu&#231;&#227;o cl&#237;nica e laboratorial, sem recorr&#234;ncia no seguimento ambulatorial.</p>
      <p>Outro achado de relev&#226;ncia &#233; a presen&#231;a de investiga&#231;&#227;o da s&#237;ndrome da Mayer&#8211;Rokitansky&#8211;K&#252;ster&#8211;Hauser a qual consiste por aplasia cong&#234;nita do &#250;tero e da parte superior (&#8532;) da vagina em mulheres com desenvolvimento dos caracteres sexuais secund&#225;rios normais. Esta s&#237;ndrome &#233; raramente associada a malforma&#231;&#245;es card&#237;acas e quando presente envolvem desfechos letais ou graves, semelhante a s&#237;ndrome de Holt-Oram ou velocardiofacial (CIA, CIV, bloqueio AV ou tetralogia de Fallot).<sup><xref ref-type="bibr" rid="B9">9</xref></sup> Em nosso caso, mantivemos vigil&#226;ncia e orienta&#231;&#227;o de seguir acompanhamento com especialidade ginecol&#243;gica.</p>
      <p>Em conjunto, este relato refor&#231;a a import&#226;ncia de considerar o quiloperic&#225;rdio no diagn&#243;stico diferencial de derrames peric&#225;rdicos e a necessidade de uma ampla variedade de exames para identifica&#231;&#227;o da etiologia. O reconhecimento precoce, a an&#225;lise detalhada do l&#237;quido peric&#225;rdico e a investiga&#231;&#227;o etiol&#243;gica sistem&#225;tica s&#227;o fundamentais para orientar o manejo e reduzir o risco de recorr&#234;ncia e complica&#231;&#245;es.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup></p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Groves LK, Effler DB. Primary Chylopericardium. N Engl J Med. 1954;250(12):520-3. doi: 10.1056/NEJM195403252501206.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groves</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Effler</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Primary Chylopericardium</article-title>
          <source>N Engl J Med</source>
          <year>1954</year>
          <volume>250</volume>
          <issue>12</issue>
          <fpage>520</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM195403252501206</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Dib C, Tajik AJ, Park S, Kheir ME, Khandieria B, Mookadam F. Chylopericardium in Adults: A Literature Review Over the Past Decade (1996-2006). J Thorac Cardiovasc Surg. 2008;136(3):650-6. doi: 10.1016/j.jtcvs.2008.03.033.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dib</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kheir</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Khandieria</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mookadam</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Chylopericardium in Adults: A Literature Review Over the Past Decade (1996-2006)</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>2008</year>
          <volume>136</volume>
          <issue>3</issue>
          <fpage>650</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2008.03.033</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Riquet M, Le Pimpec-Barthes F, Hidden G. Lymphatic Drainage of the Pericardium to the Mediastinal Lymph Nodes. Surg Radiol Anat. 2001;23(5):317-9. doi: 10.1007/s00276-001-0317-2.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riquet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Le Pimpec-Barthes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hidden</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Lymphatic Drainage of the Pericardium to the Mediastinal Lymph Nodes</article-title>
          <source>Surg Radiol Anat</source>
          <year>2001</year>
          <volume>23</volume>
          <issue>5</issue>
          <fpage>317</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1007/s00276-001-0317-2</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Rochefort MM. Review of Chylopericardium. Mediastinum. 2022;6:3. doi: 10.21037/med-20-64.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rochefort</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Review of Chylopericardium</article-title>
          <source>Mediastinum</source>
          <year>2022</year>
          <volume>6</volume>
          <size units="pages">3</size>
          <pub-id pub-id-type="doi">10.21037/med-20-64</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Verma B, Kumar A, Verma N, Agrawal A, Yesilyaprak A, Furqan MM, et al. Clinical Characteristics, Evaluation and Outcomes of Chylopericardium: A Systematic Review. Heart. 2023;109(17):1281-5. doi: 10.1136/heartjnl-2022-321798.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verma</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yesilyaprak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Furqan</surname>
              <given-names>MM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Clinical Characteristics, Evaluation and Outcomes of Chylopericardium: A Systematic Review</article-title>
          <source>Heart</source>
          <year>2023</year>
          <volume>109</volume>
          <issue>17</issue>
          <fpage>1281</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="doi">10.1136/heartjnl-2022-321798</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Adler Y, Charron P, Imazio M, Badano L, Bar&#243;n-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(42):2921-64. doi: 10.1093/eurheartj/ehv318.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adler</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Charron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Imazio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Badano</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bar&#243;n-Esquivias</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bogaert</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)</article-title>
          <source>Eur Heart J</source>
          <year>2015</year>
          <volume>36</volume>
          <issue>42</issue>
          <fpage>2921</fpage>
          <lpage>2964</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehv318</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Chylopericardium: Clinical Features, Diagnosis, and Management. In: Post TW, editor. UpToDate [Internet]. Waltham: UpToDate Inc.; 2025 [cited 2026 Jun 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.uptodate.com">https://www.uptodate.com</ext-link>.</mixed-citation>
        <element-citation publication-type="webpage">
          <chapter-title>Chylopericardium: Clinical Features, Diagnosis, and Management</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Post</surname>
              <given-names>TW</given-names>
            </name>
            <role>editor</role>
          </person-group>
          <source>UpToDate</source>
          <comment>Internet</comment>
          <publisher-loc>Waltham</publisher-loc>
          <publisher-name>UpToDate Inc</publisher-name>
          <year>2025</year>
          <date-in-citation content-type="cited-date">cited 2026 Jun 30</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.uptodate.com">https://www.uptodate.com</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous Pericarditis. Circulation. 2005;112(23):3608-16. doi: 10.1161/CIRCULATIONAHA.105.543066.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayosi</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Doubell</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Tuberculous Pericarditis</article-title>
          <source>Circulation</source>
          <year>2005</year>
          <volume>112</volume>
          <issue>23</issue>
          <fpage>3608</fpage>
          <lpage>3616</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.543066</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Morcel K, Camborieux L; Programme de Recherches sur les Aplasies M&#252;ll&#233;riennes; Guerrier D. Mayer-Rokitansky-K&#252;ster-Hauser (MRKH) Syndrome. Orphanet J Rare Dis. 2007;2:13. doi: 10.1186/1750-1172-2-13.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morcel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Camborieux</surname>
              <given-names>L</given-names>
            </name>
            <collab>Programme de Recherches sur les Aplasies M&#252;ll&#233;riennes</collab>
            <name>
              <surname>Guerrier</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Mayer-Rokitansky-K&#252;ster-Hauser (MRKH) Syndrome</article-title>
          <source>Orphanet J Rare Dis</source>
          <year>2007</year>
          <volume>2</volume>
          <size units="pages">13</size>
          <pub-id pub-id-type="doi">10.1186/1750-1172-2-13</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <label>Vincula&#231;&#227;o Acad&#234;mica:</label>
        <p> N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other">
        <label>Aprova&#231;&#227;o &#201;tica e Consentimento Informado:</label>
        <p> Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Hospital S&#237;rio-liban&#234;s sob o n&#250;mero de protocolo 96535426.4.0000.5461. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013.</p>
      </fn>
      <fn fn-type="other">
        <label>Uso de Intelig&#234;ncia Artificial:</label>
        <p> Os autores n&#227;o utilizaram ferramentas de intelig&#234;ncia artificial no desenvolvimento deste trabalho.</p>
      </fn>
      <fn fn-type="data-availability" specific-use="data-available-upon-request">
        <label>Disponibilidade de Dados:</label>
        <p> Todo o conjunto de dados que d&#225; suporte aos resultados deste estudo est&#225; dispon&#237;vel mediante solicita&#231;&#227;o ao autor correspondente</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <label>Fontes de Financiamento:</label>
        <p> O presente estudo n&#227;o teve fontes de financiamento externas.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20260066i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Idiopathic Primary Chylopericardium</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0001-9656-8703</contrib-id>
          <name>
            <surname>Ruffo</surname>
            <given-names>Camila Helena</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Writing of the manuscript</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8060-221X</contrib-id>
          <name>
            <surname>Rosa</surname>
            <given-names>Alfredo Aur&#233;lio Marinho</given-names>
            <suffix>Filho</suffix>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0003-4633-8429</contrib-id>
          <name>
            <surname>Favaro</surname>
            <given-names>Guilherme Lima</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-3842-8355</contrib-id>
          <name>
            <surname>Hirose</surname>
            <given-names>Juliana Sayuri Maia</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0000-5307-890X</contrib-id>
          <name>
            <surname>Lewinter</surname>
            <given-names>Raissa Matias</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0009-0856-4357</contrib-id>
          <name>
            <surname>Melillo</surname>
            <given-names>Natan</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0003-4756-7258</contrib-id>
          <name>
            <surname>Silva</surname>
            <given-names>Leonardo Izzo</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0009-0002-7010-6305</contrib-id>
          <name>
            <surname>Anbar</surname>
            <given-names>Ramez</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coelho</surname>
            <given-names>Murilo Martins</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1010-2428</contrib-id>
          <name>
            <surname>Generoso</surname>
            <given-names>Giuliano</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Writing of the manuscript</role>
          <role>Critical revision of the manuscript for intellectual content</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital S&#237;rio - Liban&#234;s, S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001"><label>Mailing Address:</label> Camila Helena Ruffo Hospital S&#237;rio - Liban&#234;s &#8211; Rua Prof. Daher Cutait, 69. Postal Code 01308-060, S&#227;o Paulo, SP &#8211; Brazil E-mail: camilahruffo@gmail.com </corresp>
        <fn fn-type="coi-statement">
          <label>Potential Conflict of Interest:</label>
          <p> No potential conflict of interest relevant to this article was reported.</p>
        </fn>
        <fn fn-type="edited-by">
          <label>Editor responsible for the review:</label>
          <p> Gl&#225;ucia Maria Moraes de Oliveira</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords:</title>
        <kwd>Pericardium</kwd>
        <kwd>Pericardial Effusion</kwd>
        <kwd>Diagnostic Imaging</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Chylopericardium is a rare entity, defined by the accumulation of chyle in the pericardial space, characterized by a high concentration of triglycerides and lymphocyte predominance. It was first described in 1954, and since then, this condition has remained infrequent, with most evidence coming from case reports and small series, which hinders early recognition and standardization of management.</p>
        <p>The main causes include congenital lymphangiectasia, iatrogenic injury after cardiac or thoracic surgery, neoplasms, trauma, infection, radiation, pulmonary hypertension, subclavian vein thrombosis, and primary or idiopathic causes. Primary chylopericardium has a variable incidence in the literature and is a diagnosis of exclusion.</p>
        <p>We report a case of primary chylopericardium in a young patient, emphasizing the diagnostic and therapeutic challenges of this rare condition.</p>
      </sec>
      <sec>
        <title>Description</title>
        <p>A 31-year-old female patient, previously healthy, born and residing in S&#227;o Paulo (SP), sought medical attention in an outpatient setting, complaining of progressive tiredness, fatigue, and exercise intolerance, which began 5 months prior. She reported dyspnea on minimal exertion, associated with dizziness, a feeling of imbalance, and daytime sweating, with gradual worsening over the months. She denied chest pain, fever, cough, weight loss, infectious symptoms, or a history of chest trauma or previous surgeries. Her personal history included bronchitis, and she was under investigation for primary amenorrhea, with suspected Mayer-Rokitansky-K&#252;ster-Hauser syndrome. She denied smoking, alcohol consumption, or illicit drug use.</p>
        <p>On initial physical examination, the patient appeared to be in good general condition, with BP: 129x67 mmHg, HR: 65 bpm, RR: 16 brpm, oxygen saturation 97% on room air, afebrile, without signs of systemic congestion, with cardiovascular and respiratory examination showing no significant alterations.</p>
        <p>The initial investigation included an electrocardiogram, laboratory tests (without specific findings), and a chest X-ray (<xref ref-type="fig" rid="f01001">Figure 1</xref>) showing a clear increase in the cardiac silhouette. Based on this finding, a transthoracic echocardiogram was requested, which revealed a moderate-volume pericardial effusion without signs of cardiac tamponade.</p>
        <p>
          <fig id="f01001">
            <label>Figure 1</label>
            <caption>
              <title>&#8211; Chest X-ray: increased cardiac silhouette.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf01-en.tif"/></fig>
        </p>
        <p>Therefore, hospital admission was chosen for the investigation of the etiology of the pericardial effusion with laboratory tests such as rheumatological, infectious, and metabolic tests, as well as complementary imaging exams.</p>
        <p>Further analysis showed normal blood count, electrolytes, urinalysis, renal, hepatic, and thyroid function, in addition to slightly altered inflammatory markers: CRP: 1.02 mg/dL (reference range &lt;0.5 mg/dL) and ESR: 41 mm (reference range: 2-20 mm). Rheumatological evaluation demonstrated nonspecific and mild alterations, which do not determine a rheumatological diagnosis (<xref ref-type="table" rid="t1001">Table 1</xref>).</p>
        <p>
          <table-wrap id="t1001">
            <label>Table 1</label>
            <caption>
              <title>&#8211; Results of rheumatological investigation tests</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Exams</th>
                  <th>Results</th>
                  <th>Reference value</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>ANA</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>RF</td>
                  <td align="center">negative</td>
                  <td align="center">Negative</td>
                </tr>
                <tr>
                  <td>C3</td>
                  <td align="center">145 mg/dL</td>
                  <td align="center">81-157 mg/dL</td>
                </tr>
                <tr>
                  <td>C4</td>
                  <td align="center">46 mg/dL</td>
                  <td align="center">13-39 mg/dL</td>
                </tr>
                <tr>
                  <td>ASO</td>
                  <td align="center">592 IU/mL</td>
                  <td align="center">&lt;200UI/mL</td>
                </tr>
                <tr>
                  <td>Lupus anticoagulant</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-DsDNA</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-Jo 1</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-SCL 70</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-SSBLA</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-SSBR</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-Sm</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anti-RNP</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Anticardiolipin</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Alpha-1 acid glycoprotein</td>
                  <td align="center">73 mg/dL</td>
                  <td align="center">50-120 mg/dL</td>
                </tr>
                <tr>
                  <td>ANCA</td>
                  <td align="center">negative</td>
                  <td align="center">negative</td>
                </tr>
                <tr>
                  <td>Urinary creatinine</td>
                  <td align="center">20 mg/kg/day</td>
                  <td align="center">11-20 mg/kg/day</td>
                </tr>
                <tr>
                  <td>Protein electrophoresis</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td>Albumin</td>
                  <td align="center">53%</td>
                  <td align="center">55-66%</td>
                </tr>
                <tr>
                  <td>Beta-globulin</td>
                  <td align="center">6.5%</td>
                  <td align="center">3.2-6.5%</td>
                </tr>
                <tr>
                  <td>Gamma-globulin</td>
                  <td align="center">21%</td>
                  <td align="center">11-18%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN1001">
                <p>ANA: antinucleus factor; RF: rheumatoid factor; C3: complement C3; C4: complement C4; ASO: antistreptolysin O; Anti-DSDNA: anti native DNA antibody; Anti-Jo1: anti-Jo1 antibody; Anti-SCL70: anti-SCL70 antibody; Anti-SSBLA: anti SSBLA antibody; Anti-SSARo: anti SSARo antibody; Anti-SM: anti SM antibody; Anti-RNP: anti RNP antibody; ANCA: anti-neutrophil cytoplasmic antibodies.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>For better anatomical definition, she underwent cardiac magnetic resonance imaging, which demonstrated preserved biventricular systolic function, absence of myocardial fibrosis, and presence of pericardial effusion without other alterations (<xref ref-type="fig" rid="f02001">Figure 2</xref>).</p>
        <p>
          <fig id="f02001">
            <label>Figure 2</label>
            <caption>
              <title>&#8211; Cardiac Magnetic Resonance Imaging demonstrating pericardium with slight thickening and mild to moderate effusion.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf02-en.tif"/></fig>
        </p>
        <p>At the end of the investigation, the patient was discharged with empirical treatment for possible viral pericarditis consisting of colchicine 0.5 mg twice daily and ibuprofen 400 mg twice daily, with partial improvement of symptoms after 4 weeks.</p>
        <p>A follow-up transthoracic echocardiogram was performed after 4 weeks and identified increased pericardial effusion (25mm), increased echogenicity, and swing heart. (<xref ref-type="fig" rid="f03001">Figure 3</xref>). Based on this finding, she was referred to the emergency room in good general condition, asymptomatic, with BP: 111x59 mmHg, HR: 58 bpm, RR: 13 brpm, and oxygen saturation 97% on room air, normal physical examination, and no clinical signs of cardiac tamponade. The electrocardiogram showed a single finding of ST-segment elevation, mild and diffuse, of the early repolarization type - a common finding in young people, nonspecific, and which persisted throughout the hospitalization (<xref ref-type="fig" rid="f04001">Figure 4</xref>).</p>
        <p>
          <fig id="f03001">
            <label>Figure 3</label>
            <caption>
              <title>&#8211; Transthoracic echocardiogram. 1- Long-axis longitudinal window. 2- Short-axis longitudinal window. 3- Apical 4-chamber window. 4- Subxiphoid window demonstrating right ventricular filling restriction. Arrows: pericardial effusion.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf03-en.tif"/></fig>
        </p>
        <p>
          <fig id="f04001">
            <label>Figure 4</label>
            <caption>
              <title>&#8211; Sinus rhythm, preserved axis, slight diffuse ST elevation, and no signs suggestive of cardiac tamponade.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf04-en.tif"/></fig>
        </p>
        <p>Therefore, an urgent pericardial drainage was performed with the aid of video-assisted thoracoscopy, resulting in the removal of 400 mL of thick, yellowish, chylous fluid, and a thickened, fibrinous pericardium was visualized. (<xref ref-type="fig" rid="f05001">Figure 5</xref>) Analysis of the pericardial fluid revealed triglycerides of 984 mg/dL, total cholesterol of 83 mg/dL, a cholesterol/triglyceride ratio of 0.08, and a predominance of lymphocytes (89%), confirming the diagnosis of chylopericardium. The patient&#8217;s lipid profile showed total cholesterol (TC): 174 mg/dL, triglycerides (TG): 35 mg/dL, LDL-c: 116 mg/dL, and HDL-c: 47 mg/dL. Further analysis of the pericardial fluid showed pH: 7.4, protein: 4.4 g/L, LDH: 153 mg/dL, albumin: 2.9 g/L, amylase: 93 mg/dL, and glucose: 90 mg/dL. Tuberculosis tests (ADA, AFB, and TB-TR) were negative. CMV-PCR, direct mycological examination, oncotic cytology, and cultures were all negative. Pericardial biopsy demonstrated chronic fibrinous pericarditis in the organizing phase.</p>
        <p>
          <fig id="f05001">
            <label>Figure 5</label>
            <caption>
              <title>&#8211; Macroscopic appearance of pericardial fluid.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf05-en.tif"/></fig>
        </p>
        <p>Based on the confirmed diagnosis of chylopericardium, the etiological investigation included a chest computed tomography scan, which showed no abnormalities or masses, and lymphoscintigraphy (<xref ref-type="fig" rid="f06001">Figure 6</xref>), which demonstrated diffuse functional lymphatic drainage deficit, without signs of dermal reflux (a sign of lymphedema), obstruction or dilation of lymphatic vessels, anomalous drainage, or increased uptake in lymph node regions.</p>
        <p>
          <fig id="f06001">
            <label>Figure 6</label>
            <caption>
              <title>&#8211; Lymphoscintigraphy is performed by injecting a radiopharmaceutical subcutaneously between the fingers and toes, which is then absorbed by the lymphatic system and transported along the lymphatic vessels; it is used to assess lymphatic flow, vessel integrity, lymph nodes, and dermal reflux (present in cases of lymphedema). The patient in question presented findings of diffuse functional deficit of lymphatic drainage. There was no evidence of obstructions, congenital malformations, or lymphatic duct fistulas.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-123-07-e20260062-60066-gf06-en.tif"/></fig>
        </p>
        <p>With secondary causes ruled out, the patient received treatment for primary chylopericardium with a low-fat, high-protein diet, along with maintenance of pericardial drainage.</p>
        <p>In the postoperative period, blood pressure fluctuated between 100-138/59-85 mmHg, heart rate between 51-95 bpm, and respiratory rate between 13-20 breaths per minute. Daily assessments showed a progressive reduction in pericardial fluid output and a sustained decrease in triglyceride levels, leading to the decision to remove the drain 10 days after the procedure. The follow-up transthoracic echocardiogram showed no signs of pericardial effusion, and the patient was discharged after 11 days of hospitalization (<xref ref-type="table" rid="t2001">Table 2</xref>).</p>
        <p>
          <table-wrap id="t2001">
            <label>Table 2</label>
            <caption>
              <title>&#8211; Temporality of events in the case</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Event</th>
                  <th>Time / Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Onset of symptoms</td>
                  <td align="center">5 months before the first consultation</td>
                </tr>
                <tr>
                  <td>1st outpatient consultation</td>
                  <td align="center">Day 0 (reference)</td>
                </tr>
                <tr>
                  <td>ECG, chest X-ray, initial laboratory tests</td>
                  <td align="center">Day 2</td>
                </tr>
                <tr>
                  <td>Transthoracic echocardiogram &#8211; moderate pericardial effusion without tamponade</td>
                  <td align="center">Day 7</td>
                </tr>
                <tr>
                  <td>Hospital admission for etiological investigation.</td>
                  <td align="center">Day 13</td>
                </tr>
                <tr>
                  <td>Expanded laboratory tests (rheumatological, infectious, metabolic)</td>
                  <td align="center">During the first hospitalization</td>
                </tr>
                <tr>
                  <td>Cardiac magnetic resonance imaging &#8211; preserved function, pericardial effusion without other abnormalities.</td>
                  <td align="center">During the first hospitalization</td>
                </tr>
                <tr>
                  <td>Hospital discharge with empirical treatment (colchicine + ibuprofen)</td>
                  <td align="center">Day 7 of the first hospitalization</td>
                </tr>
                <tr>
                  <td>Outpatient follow-up with echocardiogram &#8211; appearance of the effusion (25mm), swing heart.</td>
                  <td align="center">Week 4 post-discharge</td>
                </tr>
                <tr>
                  <td>Referral to the emergency room</td>
                  <td align="center">Week 4</td>
                </tr>
                <tr>
                  <td>Video-assisted pericardial drainage &#8211; drainage of 400 mL of chylous fluid.</td>
                  <td align="center">Day 1 of the 2nd hospitalization</td>
                </tr>
                <tr>
                  <td>Analysis of pericardial fluid &#8211; confirmed diagnosis of chylopericardium</td>
                  <td align="center">Day 2 of the 2nd hospitalization</td>
                </tr>
                <tr>
                  <td>Chest CT scan and lymphoscintigraphy &#8211; complementary etiological investigation</td>
                  <td align="center">Day 3 of the 2nd hospitalization</td>
                </tr>
                <tr>
                  <td>Removal of the pericardial drain</td>
                  <td align="center">Day 10 post-surgery</td>
                </tr>
                <tr>
                  <td>Follow-up echocardiogram &#8211; no stroke</td>
                  <td align="center">Day 11 post-surgery</td>
                </tr>
                <tr>
                  <td>Hospital discharge</td>
                  <td align="center">Day 11 of the 2nd hospitalization</td>
                </tr>
                <tr>
                  <td>Outpatient follow-up</td>
                  <td align="center">After discharge, no recurrence.</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN2001">
                <p>ECG: electrocardiogram; CT: computed tomography.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>Currently, the patient is under outpatient follow-up, asymptomatic, and with favorable progress. Follow-up echocardiograms were performed after 3, 6 months, and 1 year without a new episode of pericardial effusion.</p>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>Chylopericardium is a rare condition characterized by the accumulation of triglyceride-rich lymphatic fluid (chyle) in the pericardial space. Since Groves&#8217; first report<sup><xref ref-type="bibr" rid="B1">1</xref></sup> in 1954, this condition has remained infrequent, with most knowledge derived from case reports and small series, contributing to limitations in diagnostic and therapeutic standardization. A meta-analysis conducted by the Mayo Clinic found only 33 cases in a decade of study, between 1996 and 2006.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>Lymphatic drainage of the pericardium is primarily directed to the mediastinal and peritracheobronchial lymph nodes (75%) or ascending to the brachiocephalic veins (25%). There are no reports of lymphatic vessels entering directly into the pericardial space that could cause chyle accumulation in the cavity; all remain on the pleural side of the fibrous pericardium. However, the most likely pathophysiological mechanism for the presence of chyle in the pericardial space would be due to reflux from the mediastinal and tracheobronchial lymphatic vessels.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
        <p>The clinical picture is variable and nonspecific. Most patients remain asymptomatic, while others present with progressive dyspnea, fatigue, exercise intolerance, and, in severe cases, cardiac tamponade.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> According to recent meta-analyses, approximately 74% of patients presented with symptoms at the time of diagnosis, with dyspnea being the most common, and 38% with cardiac tamponade,<sup><xref ref-type="bibr" rid="B5">5</xref></sup> with an interval between the onset of symptoms and diagnosis of approximately 13 years.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> The insidious clinical course observed in the present case is consistent with this pattern described in the literature.</p>
        <p>The epidemiology is uncertain, with more recent studies suggesting that up to 60% of cases are primary idiopathic, predominantly affecting young adults, with no clear predominance between the sexes.2,5 Secondary causes include cardiac or thoracic surgery, trauma, lymphatic neoplasms or other mediastinal neoplasms (mediastinal lymphangioma, mediastinal dysgerminoma, signet ring cell carcinoma), Gorham&#8217;s syndrome, radiotherapy, infections, tuberculosis, pulmonary hypertension, venous thrombosis, and mediastinal lymphangiectasia.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup> In the absence of these factors, as in the case presented, the diagnosis of primary chylopericardium should be considered one of exclusion. It is believed that the accumulation of lymphatic fluid occurs due to abnormal communications between the thoracic duct and the pericardial lymphatic vessels or due to increased pressure in the thoracic duct, as occurs in lymphangiectasia.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>Etiological investigation should be systematic, especially in cases with no apparent cause. The European Society of Cardiology (ESC) guidelines recommend targeted etiological investigation in large, recurrent, or undetermined pericardial effusions.<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
        <p>The definitive diagnosis is based on analysis of the pericardial fluid. Triglyceride levels above 500 mg/dl, a cholesterol/triglyceride ratio below 1, lymphocyte predominance, and a milky or yellowish macroscopic appearance are widely accepted criteria for diagnostic confirmation.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Cultures are usually negative, since chyle has bacteriostatic properties.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> In our case, the laboratory findings of the pericardial fluid were consistent with the literature, allowing confirmation of the diagnosis.</p>
        <p>Due to the high incidence of tuberculosis in our country, specific analyses were performed and compared with findings from the literature. Pericardial effusion due to tuberculosis generally presents as hemorrhagic, exudative, with a high protein content, and leukocytes with a predominance of lymphocytes and monocytes.<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Our findings are consistent with the possibility of tuberculosis, in addition to negative results for ADA, AFB, TB-TR, culture, and histological analysis.</p>
        <p>Transthoracic echocardiography is the initial examination of choice for evaluating pericardial effusion and hemodynamic repercussions. Other complementary imaging methods, such as computed tomography and cardiac magnetic resonance imaging, are useful for excluding neoplasms and other secondary causes.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup> Other ways to assess lymphatic drainage include ingesting Sudan III dye or a type of triglyceride labeled with radioactive iodine.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Lymphoscintigraphy and lymphangiography help identify alterations in the thoracic duct or anomalous lymphatic communications, being particularly indicated in recurrent or refractory cases.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
        <p>In this report, the patient presents with a functional lymphatic drainage deficit, showing no obstructions, abnormal communications, or dermal reflux. This finding was interpreted as constitutional to the patient, since she did not present with edema or signs of fluid retention throughout her hospitalization.</p>
        <p>Therapeutic management remains challenging due to a scarcity of robust data. Conservative strategies include pericardial drainage combined with a low-fat diet, preferably with medium-chain triglycerides, nutritional support, and, in selected cases, the use of octreotide.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup> Despite this, approximately one-third of patients experience failure of clinical treatment, requiring surgical intervention, such as thoracic duct ligation and creation of a pericardial window.<sup><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> In the case presented, treatment with pericardial drainage combined with a low-fat diet was effective, with clinical and laboratory resolution, without recurrence in outpatient follow-up.</p>
        <p>Another relevant finding is the presence of investigation for Mayer&#8211;Rokitansky&#8211;K&#252;ster&#8211;Hauser syndrome, which consists of congenital aplasia of the uterus and the upper part (&#8532;) of the vagina in women with normal development of secondary sexual characteristics. This syndrome is rarely associated with cardiac malformations and, when present, involves lethal or severe outcomes, similar to Holt-Oram syndrome or velocardiofacial syndrome (ASD, VSD, AV block or tetralogy of Fallot).<sup><xref ref-type="bibr" rid="B9">9</xref></sup> In our case, we maintained surveillance and advised the patient to continue follow-up with a gynecological specialist.</p>
        <p>Taken together, this report reinforces the importance of considering chylopericardium in the differential diagnosis of pericardial effusions and the need for a wide variety of tests to identify the etiology. Early recognition, detailed analysis of pericardial fluid, and systematic etiological investigation are fundamental to guiding management and reducing the risk of recurrence and complications.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup></p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <label>Study Association:</label>
          <p> This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other">
          <label>Ethics Approval and Consent to Participate:</label>
          <p> This study was approved by the Ethics Committee of the S&#237;rio-liban&#234;s under the protocol number 96535426.4.0000.5461. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013</p>
        </fn>
        <fn fn-type="other">
          <label>Use of Artificial Intelligence:</label>
          <p> The authors did not use any artificial intelligence tools in the development of this work.</p>
        </fn>
        <fn fn-type="data-availability" specific-use="data-available-upon-request">
          <label>Availability of Research Data:</label>
          <p> All datasets supporting the results of this study are available upon request from the corresponding author.</p>
        </fn>
        <fn fn-type="financial-disclosure">
          <label>Sources of Funding:</label>
          <p> There were no external funding sources for this study.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
